IRIS
SANTONI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.567
EU - Europa 3.072
AS - Asia 2.580
SA - Sud America 577
AF - Africa 209
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 15.016
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.498
SG - Singapore 1.030
CN - Cina 559
BR - Brasile 501
UA - Ucraina 470
IT - Italia 418
RU - Federazione Russa 402
SE - Svezia 391
IE - Irlanda 386
DE - Germania 347
HK - Hong Kong 326
TR - Turchia 193
DK - Danimarca 158
FI - Finlandia 152
CI - Costa d'Avorio 150
VN - Vietnam 143
GB - Regno Unito 142
KR - Corea 98
IN - India 93
FR - Francia 52
AR - Argentina 37
CA - Canada 34
NL - Olanda 34
PL - Polonia 34
ID - Indonesia 30
JP - Giappone 30
MX - Messico 24
EE - Estonia 22
MA - Marocco 21
ZA - Sudafrica 21
BD - Bangladesh 19
BE - Belgio 19
ES - Italia 14
EC - Ecuador 11
IQ - Iraq 9
PK - Pakistan 9
CO - Colombia 7
AT - Austria 6
PY - Paraguay 6
TT - Trinidad e Tobago 6
UZ - Uzbekistan 6
CZ - Repubblica Ceca 5
EG - Egitto 5
EU - Europa 5
KE - Kenya 5
PE - Perù 5
AU - Australia 4
IL - Israele 4
SA - Arabia Saudita 4
AL - Albania 3
AZ - Azerbaigian 3
BO - Bolivia 3
CL - Cile 3
DZ - Algeria 3
KZ - Kazakistan 3
LB - Libano 3
LT - Lituania 3
TN - Tunisia 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
KG - Kirghizistan 2
LU - Lussemburgo 2
MY - Malesia 2
NP - Nepal 2
RS - Serbia 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CH - Svizzera 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GE - Georgia 1
GY - Guiana 1
HN - Honduras 1
IM - Isola di Man 1
IS - Islanda 1
JO - Giordania 1
KI - Kiribati 1
LV - Lettonia 1
MN - Mongolia 1
MU - Mauritius 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PS - Palestinian Territory 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TV - Tuvalu 1
Totale 15.016
Salva come PNG Salva come JPEG
Città #
Ashburn 860
Chandler 857
Fairfield 705
Des Moines 687
Singapore 667
Dallas 536
Jacksonville 528
Dublin 384
Wilmington 381
Hong Kong 326
Boardman 317
Woodbridge 306
Seattle 272
Houston 255
New York 239
Cambridge 195
Lawrence 159
Princeton 159
San Mateo 153
Beijing 151
Abidjan 150
The Dalles 129
Ann Arbor 126
Los Angeles 108
Centro 98
Munich 89
San Diego 78
Moscow 75
Pune 58
Hefei 53
Ho Chi Minh City 53
Columbus 43
Turku 43
São Paulo 42
Hanoi 40
Washington 40
London 39
Turin 38
Chicago 37
Marche 33
Warsaw 30
Buffalo 29
Helsinki 29
Tokyo 29
Guangzhou 27
Redmond 26
Brooklyn 24
Falls Church 22
Santa Clara 22
Shanghai 21
Ancona 20
Norwalk 20
Atlanta 19
Montreal 19
Wuhan 19
Brussels 17
Denver 17
Belo Horizonte 16
Johannesburg 15
Stockholm 15
Chennai 14
Council Bluffs 14
Jiaxing 14
Mexico City 14
Rio de Janeiro 14
San Francisco 14
Brasília 13
Jakarta 13
Rome 13
Orem 12
Seoul 12
Ankara 11
Kilburn 11
Poplar 11
Phoenix 10
Frankfurt am Main 9
Guarulhos 9
Porto Alegre 9
Wuxi 9
Curitiba 8
Fayetteville 8
Hounslow 8
Izmir 8
Manchester 8
Squinzano 8
Boston 7
Haiphong 7
Nanjing 7
New Delhi 7
Prescot 7
Campinas 6
Chengdu 6
Chiswick 6
Grimsby 6
Porto 6
Salt Lake City 6
Sorocaba 6
Strasbourg 6
Tashkent 6
Yiwu 6
Totale 10.314
Salva come PNG Salva come JPEG
Nome #
Designing novel immunocombinations in metastatic renal cell carcinoma 181
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 162
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 161
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 161
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 155
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 149
Metabolic phenotype of bladder cancer 149
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 148
Lgr5 expression, cancer stem cells and pancreatic cancer: Results from biological and computational analyses 147
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 147
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 146
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 145
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 141
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 139
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 138
Predicting future cancer burden in the United States by artificial neural networks 137
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 135
KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma 132
Microbiome and cancers, with focus on genitourinary tumors 131
Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy 130
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 129
Exploring the Spectrum of Kidney Ciliopathies 128
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 127
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 126
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 126
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 125
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 125
HER family receptor expression and prognosis in pancreatic cancer 122
Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach 122
Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States 122
An update on investigational therapies that target STAT3 for the treatment of cancer 122
Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date 121
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 120
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 120
Metabolic Alterations in Renal and Prostate Cancer 119
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 119
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 117
High CTLA-4 expression correlates with poor prognosis in thymoma patients 117
Hyponatremia in cancer patients: Time for a new approach 114
An overview of emerging immunotargets of genitourinary tumors 113
AR-V7 and prostate cancer: The watershed for treatment selection? 111
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 111
Molecular characterization of testicular germ cell tumors using tissue microdissection 111
Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials 109
Pd-l1 inhibitors for the treatment of prostate cancer 109
Is There a Role for Immunotherapy in Prostate Cancer? 109
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 108
IMPACT OF VEGF, VEGFR, PDGFR, HIF AND ERCC1 GENE POLYMORPHISMS ON THYMIC MALIGNANCIES OUTCOME 107
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 105
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 105
Trattamento del carcinoma del pancreas. Attualità e prospettive 104
Bone targeting agents in patients with metastatic prostate cancer: State of the art 104
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 104
Urinary catheters and biofilm formation 103
Present and future of personalized medicine in adult genitourinary tumors 103
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 103
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 102
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 102
Bladder cancer: molecular determinants of personalized therapy 102
Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report 101
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 100
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 100
Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. 97
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies 97
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 97
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 96
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 96
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 96
Emerging Immunotargets and Immunotherapies in Prostate Cancer 95
Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients 95
The identification of immunological biomarkers in kidney cancers 95
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 95
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 94
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 94
An update on immunotherapy in uro-oncology 93
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 92
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035) 92
Epigenetic modulations and lineage plasticity in advanced prostate cancer 92
Treating prostate cancer by antibody-drug conjugates 92
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials 91
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 90
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: A systematic review and meta-analysis 90
The route to personalized medicine in bladder cancer: where do we stand? 90
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma 89
Role of STAT3 pathway in genitourinary tumors 89
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 89
Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States 89
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 88
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 88
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. 87
Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. 87
Metabolic alterations in renal cell carcinoma 87
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 86
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 86
Renal Cell Carcinoma: genomic landscape and clinical implications 86
Immunotherapy and radiation therapy in renal cell carcinoma 85
Circulating tumor dna testing for homology recombination repair genes in prostate cancer: From the lab to the clinic 85
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 85
VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma 84
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 84
Totale 11.124
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.024
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.024
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.796 0 0 0 0 0 512 268 200 196 277 273 70
2021/20221.346 200 208 40 24 26 142 33 65 101 118 134 255
2022/20232.865 238 271 148 214 151 879 6 156 584 13 152 53
2023/20241.401 238 34 99 162 203 362 30 41 4 30 17 181
2024/20252.547 322 206 32 16 103 88 240 92 585 239 275 349
2025/20262.962 447 509 475 541 824 166 0 0 0 0 0 0
Totale 15.278